var title_f8_2_8224="Adult with CHH";
var content_f8_2_8224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adult with cartilage-hair hypoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 234px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 22-year-old woman with metaphyseal chondrodysplasia, McKusick type (cartilage-hair hypoplasia). Note disproportionately short stature, fine light hair, and genu varum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sponseller PD, Ain MC. The Skeletal Dysplasias. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8224=[""].join("\n");
var outline_f8_2_8224=null;
var title_f8_2_8225="Parasternal long view probe position";
var content_f8_2_8225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Parasternal long view probe position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows proper probe position for obtaining the parasternal long axis view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manoj Pariyadath, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8225=[""].join("\n");
var outline_f8_2_8225=null;
var title_f8_2_8226="Modified dynamic labral shear test";
var content_f8_2_8226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82892/Mod_dyn_labral_shear_video.mp4?title=Modified+dynamic+labral+shear+test\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Modified dynamic labral shear test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The modified dynamic labral shear test is performed with the patient standing, their shoulder abducted to 120 degrees, arm kept in the scapular plane, elbow flexed to 90 degrees, and their shoulder externally rotated until they feel tightness in the shoulder. The examiner then pushes the proximal humerus anteriorly, thereby providing a shear force to the glenohumeral joint, while lowering the arm from 120 degrees to 60 degrees of abduction using the other hand. External rotation is maintained throughout. A positive test elicits pain or a painful clicking or catching sensation at the posterior joint line when the arm is abducted between 120 degrees and 90 degrees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8226=[""].join("\n");
var outline_f8_2_8226=null;
var title_f8_2_8227="TEE aortic regurgitation";
var content_f8_2_8227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/54254/teeaoreg_conv.mp4?title=TEE+aortic+regurgitation\" style=\"width:431px;height:322px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiogram with color flow Doppler bicuspid aortic valve with aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram with color flow Doppler shows a significant degree of aortic regurgitation in a patient with a bicuspid aortic valve.",
"    <div class=\"footnotes\">",
"     MV: mitral valve leaflet; Ao: aorta; LV: left ventricle; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8227=[""].join("\n");
var outline_f8_2_8227=null;
var title_f8_2_8228="Olopatadine (ophthalmic): Patient drug information";
var content_f8_2_8228=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Olopatadine (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/43/20147?source=see_link\">",
"     see \"Olopatadine (ophthalmic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9502830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pataday&trade;;",
"     </li>",
"     <li>",
"      Patanol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9502831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pataday&trade;;",
"     </li>",
"     <li>",
"      Patanol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to olopatadine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat contact lens irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 10 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12274 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8228=[""].join("\n");
var outline_f8_2_8228=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502830\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502831\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024452\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024451\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024456\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024457\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024459\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024454\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024455\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024460\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024461\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32404?source=related_link\">",
"      Olopatadine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/60/35779?source=related_link\">",
"      Olopatadine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/43/20147?source=related_link\">",
"      Olopatadine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_2_8229="Insulin aspart protamine and insulin aspart: Patient drug information";
var content_f8_2_8229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Insulin aspart protamine and insulin aspart: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/36/3655?source=see_link\">",
"     see \"Insulin aspart protamine and insulin aspart: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/50/5926?source=see_link\">",
"     see \"Insulin aspart protamine and insulin aspart: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2169301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NovoLOG&reg; Mix 70/30;",
"     </li>",
"     <li>",
"      NovoLOG&reg; Mix 70/30 FlexPen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4782805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      NovoMix&reg; 30",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to insulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2841939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood sugar.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696704",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep workouts the same. More workouts may lower your insulin needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use out dated insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2807179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not mix this insulin in the same syringe with other types of insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 15 minutes before or right after a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give a missed shot as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next shot, skip the missed shot and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened containers in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699214",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store opened vials at room temperature or in a refrigerator. If stored at room temperature, throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2847066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened pens at room temperature. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11543 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8229=[""].join("\n");
var outline_f8_2_8229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2169301\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4782805\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018702\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018701\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018706\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018707\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018709\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018704\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018705\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018710\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018711\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/36/3655?source=related_link\">",
"      Insulin aspart protamine and insulin aspart: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/50/5926?source=related_link\">",
"      Insulin aspart protamine and insulin aspart: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_2_8230="CPAM type 1 histology";
var content_f8_2_8230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histology of a type 1 congenital pulmonary airway malformation (CPAM)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histology specimend from a congenital pulmonary airway malformation (CPAM) type 1, showing the large cystic component lined by columnar, ciliated epithelium. The wall of the cyst resembles pre-acinar airways. Frequent openings in the cyst wall extend into the adjacent acinar structures. The wall contains smooth muscle but not cartilage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher M Oermann, MD, and Claire Langston, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8230=[""].join("\n");
var outline_f8_2_8230=null;
var title_f8_2_8231="Liposomal vincristine: Drug information";
var content_f8_2_8231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liposomal vincristine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/1/33812?source=see_link\">",
"    see \"Liposomal vincristine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F14793786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14793788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Natural Source (Plant) Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Vinca Alkaloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14957492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Vincristine liposomal and conventional vincristine are",
"     <b>",
"      NOT",
"     </b>",
"     interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration. The liposomal vincristine dose is based on actual body surface area (BSA) and was not capped in studies (O&rsquo;Brien, 2009; Rodriguez, 2009; Silverman, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL; Philadelphia chromosome-negative), relapsed:",
"     </b>",
"     I.V.: 2.25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 7 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14957493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14957494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, liposomal vincristine is minimally excreted by the kidney and like the conventional formulation, likely does not require dosage adjustment in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14957495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment (Child-Pugh class B): In a study in a limited number of melanoma patients with moderate (Child-Pugh class B) hepatic impairment secondary to liver metastases, C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC were comparable to those in patients with normal hepatic function; patients with hepatic impairment received a dose of 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks versus 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in subjects with normal hepatic function (Bedikian, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh class C): No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatotoxicity during treatment: Reduce dose or interrupt treatment.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F14957463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Fatigue, severe:",
"     </i>",
"     Consider dose delay, reduction, or therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Hematologic toxicity:",
"     </i>",
"     Grade 3 or 4 neutropenia, thrombocytopenia, or anemia: Consider dose reduction or modification.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Hepatic toxicity:",
"     </i>",
"     Reduce dose or interrupt treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Peripheral neuropathy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 3 or persistent grade 2 toxicity: Interrupt therapy until recovery to grade 1 or 2, then reduce dose to 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . If grade 3 toxicity persists or if grade 4 toxicity occurs, discontinue liposomal vincristine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Persistent grade 2 toxicity after first dose reduction to 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     : Interrupt therapy for up to 7 days until recovery to grade 1, then reduce dose to 1.825 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . If neuropathy increases to grade 3 or 4, discontinue liposomal vincristine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Persistent grade 2 toxicity after second dose reduction to 1.825 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     : Interrupt therapy for up to 7 days until recovery to grade 1, then reduce dose to 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . If neuropathy increases to grade 3 or 4, discontinue liposomal vincristine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pre-existing neuropathy, severe: Assess treatment benefit versus risk.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14957223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F14793791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Marqibo&reg;: FDA approved August 9, 2012; availability is currently undetermined. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14957496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vesicant; avoid extravasation.",
"     <b>",
"      For I.V. administration only. FATAL IF GIVEN INTRATHECALLY.",
"     </b>",
"     Liposomal vincristine should",
"     <b>",
"      NOT",
"     </b>",
"     be delivered to the patient at the same time as any medications intended for central nervous system administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     I.V.: Infuse over 1 hour. Do not administer I.V. push or bolus; do not use with in-line filters. Infusion must be completed within 12 hours of preparation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14957367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; do not mix with other medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14793790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in adult patients whose disease has progressed after two or more antileukemic therapies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14957222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       VinCRIStine liposomal may be confused with vinCRIStine conventional",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Conventional vincristine may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vincristine liposomal and conventional vincristine are",
"       <b>",
"        NOT",
"       </b>",
"       interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       For I.V. administration only. Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Liposomal vincristine should",
"       <b>",
"        NOT",
"       </b>",
"       be prepared during the preparation of any intrathecal medications. After preparation, keep liposomal vincristine in a location",
"       <b>",
"        away",
"       </b>",
"       from the separate storage location recommended for intrathecal medications. Liposomal vincristine should",
"       <b>",
"        NOT",
"       </b>",
"       be delivered to the patient at the same time with any medications intended for central nervous system administration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14943497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (43%), fatigue (41%), insomnia (32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (57%), nausea (52%), diarrhea (37%), appetite decreased (33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenic fever (38%; grades 3/4: 31%), anemia (34%; grades 3/4: 17%), neutropenia (grades 3/4: 18%), thrombocytopenia (grades 3/4: 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (grades 3/4: 6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (39%; grades 3/4: 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Cardiac arrest (grades 3/4: 6%), hypotension (grades 3/4: 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Pain (grades 3/4: 8%), mental status changes (grades 3/4: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (grades 3/4: 8%), ileus (grades 3/4: 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (grades 3/4: 5%), muscle weakness (grades 3/4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pneumonia (grades 3/4: 8%), respiratory distress (grades 3/4: 6%), respiratory failure (grades 3/4: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Septic shock (grades 3/4: 6%), staphylococcal bacteremia (grades 3/4: 6%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14958178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hypersensitivity to vincristine, liposomal vincristine, or any component of the formulation; patients with Charcot-Marie-Tooth syndrome or other demyelinating conditions; administration via the intrathecal route",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14957225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Grade 3 and greater neutropenia, anemia, and thrombocytopenia were observed in clinical trials. Monitor blood counts closely and adjust dose or withhold therapy if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation: Constipation, ileus, bowel obstruction, and colonic pseudo-obstruction have occurred with liposomal vincristine. Patients should be initiated on a prophylactic bowel regimen including a stool softener, dietary fiber, and hydration; laxative treatments may be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fatigue: Severe fatigue was noted in clinical trials; treatment delay, dosage adjustment or discontinuation may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Hepatotoxicity (including fatal cases) and increased AST have been reported. Monitor hepatic function tests; reduce dose or interrupt therapy if necessary. Use caution in patients with hepatic impairment; conventional vincristine undergoes extensive hepatic metabolism. Liposomal vincristine has not been studied in patients with severe hepatic impairment. In a study in a limited number of melanoma patients with moderate (Child-Pugh class B) hepatic impairment secondary to liver metastases, C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC were comparable to those in patients with normal hepatic function; patients with hepatic impairment received a dose of 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks versus 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in subjects with normal hepatic function (Bedikian, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: Neuropathies (sensory and motor) are common and cumulative. Neuropathy symptoms may include paresthesia, hyper-/hypoesthesia, hyporeflexia or areflexia, neuralgia, jaw pain, cranial neuropathy, ileus, arthralgia, myalgia, muscle spasm, and/or weakness. Evaluate neurologic status of patients closely prior to liposomal vincristine administration; neurologic toxicity risk is greater when given to patients with preexisting neuromuscular conditions or when used concomitantly with other neurotoxic agents. Treatment delay, dosage adjustment, and/or discontinuation may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome may occur as a consequence of therapy; monitor closely for signs and symptoms and manage accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Avoid concomitant therapy with strong CYP3A4 or P-glycoprotein (P-gp)  inducers or inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly patient population; conventional vincristine may cause or exacerbate hyponatremia or syndrome of inappropriate antidiuretic hormone secretion; monitor sodium closely with therapy initiation or dosage adjustments (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Liposomal vs conventional formulation dosing:",
"     <b>",
"      [U.S. Boxed Warning]: Vincristine liposomal and conventional vincristine are NOT interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration to avoid overdoses.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; avoid eye contamination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Not for intrathecal administration:",
"     <b>",
"      [U.S. Boxed Warning]: For I.V. administration only. Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death.",
"     </b>",
"     Liposomal vincristine should",
"     <b>",
"      NOT",
"     </b>",
"     be prepared during the preparation of any intrathecal medications. After preparation, keep liposomal vincristine in a location",
"     <b>",
"      away",
"     </b>",
"     from the separate storage location recommended for intrathecal medications. Liposomal vincristine should",
"     <b>",
"      NOT",
"     </b>",
"     be delivered to the patient at the same time with any medications intended for central nervous system administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vesicant: All vincristine formulations are vesicants; avoid extravasation. Only individuals experienced with vesicant administration should administer liposomal vincristine. Check for proper needle placement; if extravasation occurs, discontinue liposomal vincristine infusion immediately and institute appropriate extravasation management procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14975281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14975279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: May increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Consider vinca alkaloid dose adjustment.  Specific dose adjustment guidelines are not currently available.  Monitor response to vinca alkaloid therapy, including development of vinca alkaloid toxicities (e.g., gastrointestinal toxicity, neurotoxicity).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: May enhance the neurotoxic effect of VinCRIStine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14958175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14958176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events (fetal malformations, decreased fetal weight, and fetal loss) were observed in animal reproduction studies at doses less than the recommended human dose. Given the mechanism of action, adverse fetal events would be expected to occur with use in pregnant women. Women of childbearing potential should avoid becoming pregnant during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14961748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14958177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Due to the potential for adverse reactions in the nursing infant, the decision to discontinue breast-feeding or to discontinue liposomal vincristine should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14957528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets; hepatic function; signs/symptoms of peripheral neuropathy or other neurologic toxicities; sodium (in elderly patients; conventional vincristine may cause or exacerbate hyponatremia or syndrome of inappropriate antidiuretic hormone secretion); signs/symptoms of tumor lysis syndrome; symptoms of constipation; monitor infusion site for extravasation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14957368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vincristine is a cell cycle specific agent which binds to tubulin, leading to microtubule depolymerization and cellular apoptosis. The liposomal formulation increases the half-life, allowing for enhanced cytotoxic activity in tumor cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14957384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 2.7 L (Bedikian, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 45 hours (urinary half-life); dependent on rate of vincristine release from sphingosome (Bedikian, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (69%); urine (&lt;8%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8231/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bedikian AY, Silverman JA, Papadopoulos NE, et al, &ldquo;Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2011, 51(8):1205-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8231/abstract-text/20978276/pubmed\" id=\"20978276\" target=\"_blank\">",
"        20978276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bedikian AY, Vardeleon A, Smith T, et al, &ldquo;Pharmacokinetics and Urinary Excretion of Vincristine Sulfate Liposomes Injection in Metastatic Melanoma Patients,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2006, 46(7):727-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8231/abstract-text/16809798/pubmed\" id=\"16809798\" target=\"_blank\">",
"        16809798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Damon LE, Goldberg SL, Heffner LT, et al, &ldquo;Neurological Toxicity Profile of Weekly Vincristine Sulfate Liposomes Injection (Marqibo&reg;) 2.25 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      Compared to Historical Standard Vincristine Sulfate 1.4 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      , 2 mg, and 4 mg Administered Less Frequently,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):4247 [abstract 4247 from 2011 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heffner L, &ldquo;A New Formulation of Vincristine for Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Clin Adv Hematol Oncol",
"      </i>",
"      , 2011, 9(4):314-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8231/abstract-text/21558991/pubmed\" id=\"21558991\" target=\"_blank\">",
"        21558991",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'brien S, Schiller G, Damon LE, et al, &ldquo;Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo&reg;) in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-Leukemia Treatment Lines,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(22):3088 [abstract 3088 from 2009 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'brien S, Thomas DA, Heffner LT, et al, &ldquo;Marqibo&reg; (Vincristine Sulfate Liposomes Injection; VSLI) in the Treatment of Adult Patients With Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(21):2143 [abstract 2143 from 2010 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schiller GJ, Lister J, Heffner LT, et al, &ldquo;Vincristine Sulfate Liposomes Injection (Marqibo&reg;) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults With Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):4235 [abstract 4235 from 2011 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverman JA, Aulitzky WE, Lister J, et al, &ldquo;Marqibo&reg; (Vincristine Sulfate Liposomes Injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(21):2142 [abstract 2142 from 2010 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas DA, Sarris AH, Cortes J, et al, &ldquo;Phase II Study of Sphingosomal Vincristine in Patients With Recurrent or Refractory Adult Acute Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(1):120-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8231/abstract-text/16331634/pubmed\" id=\"16331634\" target=\"_blank\">",
"        16331634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86240 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8231=[""].join("\n");
var outline_f8_2_8231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14793786\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14793788\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957492\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957493\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957494\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957495\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957463\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957223\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14793791\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957496\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957367\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14793790\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957222\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14943497\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14958178\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957225\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975281\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975279\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14958175\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14958176\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961748\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14958177\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957528\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957368\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957384\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86240\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86240|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/1/33812?source=related_link\">",
"      Liposomal vincristine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_2_8232="Amlodipine, olmesartan, and hydrochlorothiazide: Drug information";
var content_f8_2_8232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amlodipine, olmesartan, and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/54/25446?source=see_link\">",
"    see \"Amlodipine, olmesartan, and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10481072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10481074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tribenzor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10481078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10481824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Not for initial therapy. Dose is individualized; combination product may be substituted for individual components in patients currently maintained on all 3 agents separately or in patients not adequately controlled with any 2 of the following antihypertensive classes: Calcium channel blockers, angiotensin II receptor blockers, and diuretics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Add-on/switch/replacement therapy: Amlodipine 5-10 mg, olmesartan 20-40 mg, and hydrochlorothiazide 12.5-25 mg once daily; dose may be titrated after 2 weeks of therapy. Maximum recommended daily dose: Amlodipine 10 mg/olmesartan 40 mg/hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10481825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients &ge;75 years of age should start amlodipine at 2.5 mg (combination product dosage form not available in this strength).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10481826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No adjustment needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use of combination not recommended; contraindicated in patients with anuria",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10481827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate hepatic impairment: Use with caution; specific dosing recommendations are not provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment: Patients with severe hepatic impairment should start amlodipine at 2.5 mg (combination product dosage form not available).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10481840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tribenzor&trade; :Olmesartan medoxomil 20 mg, amlodipine 5 mg, and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tribenzor&trade;: Olmesartan medoxomil 40 mg, amlodipine 5 mg, and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tribenzor&trade;: Olmesartan medoxomil 40 mg, amlodipine 5 mg, and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tribenzor&trade;: Olmesartan medoxomil 40 mg, amlodipine 10 mg, and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tribenzor&trade;: Olmesartan medoxomil 40 mg, amlodipine 10 mg, and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10481076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10481832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10481080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension (not for initial therapy)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10481311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions/percentages reported with combination product; also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (8%), syncope (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (6% to 9%), headache (6%), fatigue (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (3%), nausea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms (3%), joint swelling (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Urinary tract infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (4%), upper respiratory tract infection (3%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10481306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfonamide-derived drugs; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10481308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with olmesartan/amlodipine/hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; use caution during initiation, particularly in patients with heart failure, or in post-MI patients or those undergoing surgery or dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect of amlodipine is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Hypersensitivity to hydrochlorothiazide may be observed more frequently in patients with bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use of combination product in heart failure has not been studied; use with caution; may need to adjust dose, and/or concurrent diuretic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid use in patients with severe hepatic impairment. In patients with mild-to-moderate hepatic impairment, monitor for worsening of hepatic or renal function, fluid status, electrolytes, and adverse reactions. In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use valsartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution with pre-existing renal insufficiency. Avoid use in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute). May precipitate azotemia; discontinue or consider withholding if renal impairment occurs. Contraindicated in patients with anuria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10571847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Olmesartan. Management: Administer olmesartan at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of AmLODIPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10481315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease amlodipine levels. Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice (may diminish antihypertensive effect). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may enhance hypotensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10481082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10481083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10481304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10481305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrochlorothiazide is excreted into breast milk. Excretion of amlodipine and olmesartan into breast milk is not known. Use during nursing is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10481831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid salt substitutes which contain potassium. May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tribenzor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-5-12.5 mg (30): $149.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-5-12.5 mg (30): $189.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-5-25 mg (30): $189.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-10-12.5 mg (30): $189.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-10-25 mg (30): $189.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10481834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, orthostasis; baseline and periodic electrolyte panels, renal function; peripheral edema",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10481318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Amlodipine inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Olmesartan produces direct antagonism of the angiotensin II receptors, unlike the ACE inhibitors. It displaces angiotensin II from the AT1 receptor and produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10481320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8232/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8232/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gradman AH, Basile JN, Carter B, et al, &ldquo;Combination Therapy in Hypertension,&rdquo;",
"      <i>",
"       J Am Soc Hypertens",
"      </i>",
"      , 2010, 4(2):90-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8232/abstract-text/20400053/pubmed\" id=\"20400053\" target=\"_blank\">",
"        20400053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8232/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15584 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8232=[""].join("\n");
var outline_f8_2_8232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481072\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481074\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481078\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481824\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481825\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481826\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481827\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481840\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481076\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481832\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481080\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481311\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481306\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481308\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299784\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571847\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481315\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481082\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481083\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481304\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481305\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481831\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322860\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481834\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481318\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481320\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15584\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15584|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/54/25446?source=related_link\">",
"      Amlodipine, olmesartan, and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_2_8233="Hydrocodone and ibuprofen: Drug information";
var content_f8_2_8233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocodone and ibuprofen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/6/42085?source=see_link\">",
"    see \"Hydrocodone and ibuprofen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ibudone&reg;;",
"     </li>",
"     <li>",
"      Reprexain&trade;;",
"     </li>",
"     <li>",
"      Vicoprofen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vicoprofen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F180200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid);",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F180188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesic: Oral: 1 tablet every 4-6 hours as needed for pain; maximum: 5 tablets/day.",
"     <b>",
"      Note:",
"     </b>",
"     Short-term use is recommended (&lt;10 days).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F180189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; consider reduced doses. Refer to dosing in individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Hydrocodone bitartrate 2.5 mg and ibuprofen 200 mg; Hydrocodone bitartrate 5 mg and ibuprofen 200 mg; Hydrocodone bitartrate 7.5 mg and ibuprofen 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ibudone&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5/200: Hydrocodone bitartrate 5 mg and ibuprofen 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10/200: Hydrocodone bitartrate 10 mg and ibuprofen 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reprexain&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2.5/200: Hydrocodone bitartrate 2.5 mg and ibuprofen 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5/200: Hydrocodone bitartrate 5 mg and ibuprofen 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10/200: Hydrocodone bitartrate 10 mg and ibuprofen 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicoprofen&reg;: 7.5/200: Hydrocodone bitartrate 7.5 mg and ibuprofen 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F180202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089815.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089815.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F180164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (generally &lt;10 days) management of moderate-to-severe acute pain; is not indicated for treatment of such conditions as osteoarthritis or rheumatoid arthritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5978064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Reprexain&trade; may be confused with ZyPREXA&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F180198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (27%), somnolence (22%), dizziness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (22%), nausea (21%), dyspepsia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (3% to 9%), palpitation (&lt;3%), vasodilation (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety (3% to 9%), insomnia (3% to 9%), nervousness (3% to 9%), confusion (&lt;3%), fever (&lt;3%), pain (&lt;3%), thought abnormalities (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (3% to 9%), diarrhea (3% to 9%), flatulence (3% to 9%), vomiting (3% to 9%), xerostomia (3% to 9%), anorexia (&lt;3%), gastritis (&lt;3%), melena (&lt;3%), mouth ulcers (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Polyuria (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (3% to 9%), hypertonia (&lt;3%), paresthesia (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (&lt;3%), pharyngitis (&lt;3%), rhinitis (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (3% to 9%), infection (3% to 9%), flu-like syndrome (&lt;3%), hiccups (&lt;3%), thirst (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal dreams, agitation, allergic reaction, arrhythmia, arthralgia, asthma, bronchitis, chalky stool, clenching teeth, cough, cystitis, depression, dry eyes, dysphagia, esophageal spasm, esophagitis, euphoria, exfoliative dermatitis, gastroenteritis, GI bleeding, GI inflammation, GI perforation, glossitis, glycosuria, hoarseness, hyper-/hypotension, impotence, libido decreased, liver enzymes increased, mood changes, myalgia, neuralgia, pneumonia, physical/psychological dependence (with prolonged use), pulmonary congestion, rash, respiratory depression, sinusitis, slurred speech, Stevens-Johnson syndrome, tachycardia, taste (unpleasant), tremor, toxic epidermal necrolysis, ulcer, urinary incontinence, urinary retention, urticaria, vertigo, vision change, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F180167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrocodone, ibuprofen, or any component of the formulation; patients who have experienced asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F180151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk.  When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: Hydrocodone may obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenocortical insufficiency: Use with caution in patients with adrenocortical insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer NSAIDs to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use hydrocodone with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use of NSAIDs is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use hydrocodone with caution in patients with a potential for or a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use hydrocodone with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with caution in patients with toxic psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use hydrocodone with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages. May suppress cough reflex; use with caution postoperatively and in patients with pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;poor metabolizers&rdquo;: Due to the role of CYP2D6 in the metabolism of hydrocodone to hydromorphone (an active metabolite with higher binding affinity to mu-opioid receptors compared to hydrocodone), patients with genetic variations of CYP2D6, including &ldquo;poor metabolizers&rdquo; or &ldquo;extensive metabolizers,&rdquo; may have decreased or increased hydromorphone formation, respectively. Variable effects in positive and negative opioid effects have been reported in these patients; however, limited data exists to determine if clinically significant differences of analgesia and toxicity can be predicted based on CYP2D6 phenotype (Hutchinson, 2004; Otton, 1993; Zhou, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;16 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F180195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease serum concentrations of the active metabolite(s) of Hydrocodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F180180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on",
"     <b>",
"      hydrocodone",
"     </b>",
"     component: Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on",
"     <b>",
"      ibuprofen",
"     </b>",
"     component:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Food: Ibuprofen peak serum levels may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F180157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F180171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. In humans, birth defects, including some heart defects, have been associated with maternal use of opioid analgesics, including hydrocodone, during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate. Symptoms of opioid withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, respiratory rate increased, sneezing, tremors, vomiting, or yawning; respiratory depression may occur in the newborn if opioids are used prior to delivery. As with other NSAID-containing products, this agent should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. Also refer to the ibuprofen monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F180191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5630838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrocodone and ibuprofen are excreted in breast milk. In one study, the calculated dose of hydrocodone to a nursing infant was 0.2% to 9% (mean: 2.4%) of the weight-adjusted maternal dose. Hydromorphone was also measurable in 12 cases; the total opioid dose to a nursing infant was calculated to be 0.1% to 9.9% (mean: 1.5%) of the weight-adjusted maternal dose. Concentrations may be increased in women who are extensive metabolizers of CYP2D6. Caution should be used since most persons are not aware of their CYP2D6 genotype status. When hydrocodone is used in breast-feeding women, it is recommended to use the lowest dose for the shortest duration of time and observe the infant for adverse events. Some clinicians recommend limiting the dose to hydrocodone bitartrate 30 mg/day (Sauberan, 2011). The manufacturers recommend discontinuing the medication or to discontinue nursing during therapy. Also refer to the ibuprofen monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F180170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hydrocodone-Ibuprofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-200 mg (100): $292.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-200 mg (100): $310.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-200 mg (100): $114.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200 mg (100): $409.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ibudone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-200 mg (100): $86.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200 mg (100): $114.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Reprexain Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-200 mg (100): $324.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-200 mg (100): $344.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200 mg (100): $454.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vicoprofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-200 mg (100): $364.28",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6694729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs/symptoms of bleeding; periodic CBC and chemistry profile with long-term use; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F180172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dovir (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F180150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hydrocodone: Binds to opiate receptors in the CNS, altering the perception of and response to pain; suppresses cough in medullary center; produces generalized CNS depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ibuprofen: Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which result in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F180166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ibuprofen:",
"     </b>",
"     See Ibuprofen monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hydrocodone:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Narcotic analgesic: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: 19% to 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic; O-demethylation; via primarily CYP2D6 to hydromorphone (major, active metabolite with ~10- to 33-fold higher or as much as a &gt;100-fold higher binding affinity for the mu-opioid receptor than hydrocodone); N-demethylation via CYP3A4 to norhydrocodone (major metabolite); and ~40% of metabolism/clearance occurs via other non-CYP pathways, including 6-ketosteroid reduction to 6-alpha-hydrocol and 6-beta-hydrocol, and other elimination pathways (eg, fecal, biliary, intestinal, renal) (Hutchinson, 2004; Volpe, 2011; Zhou, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time to peak: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Urine (26% of single dose in 72 hours, with ~12% as unchanged drug, 5% as norhydrocodone, 4% as conjugated hydrocodone, 3% as 6-hydrocodol, and 0.21% as conjugated 6-hydromorphol (Zhou, 2009)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo;",
"      <i>",
"       Breastfeed Med",
"      </i>",
"      , 2007, 2(1):10-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/17661614/pubmed\" id=\"17661614\" target=\"_blank\">",
"        17661614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CS, Rasmussen SA, Reefhuis J, et al, \"National Birth Defects Prevention Study: Maternal Treatment With Opioid Analgesics and Risk for Birth Defects,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2011, 204(4):314.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/21345403/pubmed\" id=\"21345403\" target=\"_blank\">",
"        21345403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutchinson MR, Menelaou A, Foster DJ, et al, &ldquo;CYP2D6 and CYP3A4 Involvement in the Primary Oxidative Metabolism of Hydrocodone by Human Liver Microsomes,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2004, 57(3):287-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/14998425/pubmed\" id=\"14998425\" target=\"_blank\">",
"        14998425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina DK and Hargrove VM, &ldquo;What Is the Lethal Concentration of Hydrocodone?,&rdquo;",
"      <i>",
"       Am J Forensic Med Pathol",
"      </i>",
"      , 32(2):108-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/20407360/pubmed\" id=\"20407360\" target=\"_blank\">",
"        20407360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Otton SV, Schadel M, Cheung SW, et al, &ldquo;CYP2D6 Phenotype Determines the Metabolic Conversion of Hydrocodone to Hydromorphone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1993, 54(5):463-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/7693389/pubmed\" id=\"7693389\" target=\"_blank\">",
"        7693389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, &ldquo;Management of Nonobstetric Pain During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sauberan JB, Anderson PO, Lane JR, et al, \"Breast Milk Hydrocodone and Hydromorphone Levels in Mothers Using Hydrocodone for Postpartum Pain,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):611-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/21343764/pubmed\" id=\"21343764\" target=\"_blank\">",
"        21343764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sunshine A, Olson NZ, O'Neill E, et al, &ldquo;Analgesic Efficacy of a Hydrocodone With Ibuprofen Combination Compared With Ibuprofen Alone for the Treatment of Acute Postoperative Pain,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1997, 37:908-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/9505982/pubmed\" id=\"9505982\" target=\"_blank\">",
"        9505982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Volpe DA, McMahon Tobin GA, Mellon RD, et al, &ldquo;Uniform Assessment and Ranking of Opioid Mu Receptor Binding Constants for Selected Opioid Drugs,&rdquo;",
"      <i>",
"       Regul Toxicol Pharmacol",
"      </i>",
"      , 2011, 59(3):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/21215785 /pubmed\" id=\"21215785 \" target=\"_blank\">",
"        21215785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhou SF, &ldquo;Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2009, 48(12):761-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/2/8233/abstract-text/19902987/pubmed\" id=\"19902987\" target=\"_blank\">",
"        19902987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8637 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.211.0.116-355AF4D441-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8233=[""].join("\n");
var outline_f8_2_8233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708906\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180184\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180185\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180200\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180188\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180189\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180161\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180147\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180202\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874785\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180164\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5978064\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180198\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180167\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180151\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180195\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180156\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180180\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180157\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180171\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180191\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630838\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180170\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6694729\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180172\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180150\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180166\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8637|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/6/42085?source=related_link\">",
"      Hydrocodone and ibuprofen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_2_8234="EP study tracings RF ablation atrial flutter";
var content_f8_2_8234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69946%7ECARD%2F60090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69946%7ECARD%2F60090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of typical atrial flutter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high right atrium (HRA), a mapping catheter in the isthmus between the tricuspid valve and inferior vena cava (TV-IVC) (HBE1-2), eight recordings from a catheter extending from the lateral right atrial wall through the TV-IVC isthmus and into the ostium of the coronary sinus (CS15-1 to CS 1-2), and right ventricular apex (RVA3-4) in a patient with typical atrial flutter. The tip of the mapping catheter was initially positioned on the tricuspid annulus, and then dragged through the TV-IVC isthmus to the ostium of the IVC during RF application; atrial flutter terminated. Note that the atrial activation (A) blocks between CS7-8 and CS 5-6, which on fluoroscopy corresponded to the position of the mapping catheter.",
"    <div class=\"footnotes\">",
"     Fl: flutter waves; V: ventricular electrogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of atrial flutter showing bidirectional isthmus block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high right atrium (HRA), eight recordings from a catheter extending from the lateral right atrial wall through the tricuspid valve-inferior vena cava (TV-IVC) isthmus and into the ostium of the coronary sinus (CS15-1 through CS1-2), and right ventricular apex (RVA3-4) in a patient who has undergone ablation for atrial flutter. Left panel shows pacing (PA) from the lateral right atrial wall; the impulse is propagated down the lateral wall of the high right atrium, generating an atrial electrogram (A), to the lateral TV-IVC isthmus region (CS13-1, CS 11-1, CS9-10) where conduction is blocked. The medial aspect of the isthmus is not depolarized until a wavefront of activation comes down the interatrial septum or from the low left atrium; the distal poles of the catheter are therefore depolarized late and in the opposite direction, from the coronary sinus ostium back towards the medial TV-IVC isthmus (CS 3-4, CS 5-6, CS 7-8). Right panel shows pacing from the coronary sinus ostium. In this case, the medial isthmus is depolarized promptly (CS 3-4, CS 5-6), but conduction is blocked within the isthmus (CS7-8). Thus, activation of the lateral wall of the right atrium is delayed until a wavefront travels up the septum and across the roof of the right atrium. Activation of the proximal poles of the catheter is therefore delayed and occurs from high to low (CS 15-1, CS 13-1, CS 11-1, CS9-10). Patients with bidirectional block across the TC-IVC isthmus have a low rate of atrial flutter recurrence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8234=[""].join("\n");
var outline_f8_2_8234=null;
var title_f8_2_8235="Diabetes control for commercial driver cert";
var content_f8_2_8235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diabetes parameters for commercial driver's certification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Biochemical index",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Upper limit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Normal",
"      </td>",
"      <td class=\"subtitle2\">",
"       Acceptable",
"      </td>",
"      <td class=\"subtitle2\">",
"       Poor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fasting plasma glucose, mg/dL",
"      </td>",
"      <td>",
"       115",
"      </td>",
"      <td>",
"       140",
"      </td>",
"      <td>",
"       &sim;200",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postprandial (2-hour) plasma glucose, mg/dL",
"      </td>",
"      <td>",
"       140",
"      </td>",
"      <td>",
"       200",
"      </td>",
"      <td>",
"       &gt;235",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glycosylated hemoglobin, percent",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       &gt;10",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Adjust for normal values of laboratory.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Conference on Diabetic Disorders and Commercial Drivers, July 1988. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8235=[""].join("\n");
var outline_f8_2_8235=null;
var title_f8_2_8236="Causes of lymphocytopenia";
var content_f8_2_8236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of lymphocytopenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial (eg, tuberculosis, typhoid fever, histoplasmosis, brucellosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral (eg, HIV, severe acute respiratory syndrome [SARS], measles, hepatitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other (eg, malaria)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital immunodeficiency disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Iatrogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunosuppressive agents (eg, glucocorticoids, anti-lymphocyte globulin, alemtuzumab, rituximab)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy (eg, fludarabine, cladribine), hematopoietic cell transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation therapy (eg, total body irradiation, radiation injury)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Systemic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune disorders (eg, systemic lupus erythematosus, rheumatoid arthritis, Sj&ouml;gren syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aplastic anemia, pancytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cushing's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malnutrition, stress, exercise, trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic duct leak, rupture, diversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein-losing enteropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic CD4+ lymphocytopenia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8236=[""].join("\n");
var outline_f8_2_8236=null;
var title_f8_2_8237="Delayed clinical toxicity agents";
var content_f8_2_8237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Toxic time bombs (delayed clinical toxicity)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Acetaminophen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pennyroyal oil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon tetrachloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Mushrooms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amanita (amatoxin)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lepiota (amatoxin)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gyromitra (gyromitrin)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cortinarius (orellanine/orelline)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Toxic alcohols",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ethylene glycol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sustained-release preparations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Calcium-channel blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Beta-blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Enteric-coated preparations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Aspirin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Monoamine oxidase inhibitors",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Drug packet ingestion (heroin, cocaine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oral hypoglycemic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diphenoxylate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methylene chloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraquat/diquat",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyanogenic glycosides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Flouride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Warfarin/superwarfarin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Brodifacoum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurotoxic snake envenomation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antimetabolites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Colchicine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methotrexate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Alkylating agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fat-soluble organophosphate insecticides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ergotamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Heavy metals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lead",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thallium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mercury",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8237=[""].join("\n");
var outline_f8_2_8237=null;
var title_f8_2_8238="HBV precore-core ORF";
var content_f8_2_8238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HBV precore/core open reading frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the HBV precore/core open reading frame (ORF), RNA transcripts and translational products in wild type and precore mutant viruses. The precore region consists of 87 nucleotides coding for 29 amino acids. In the wild type virus, the precore mRNA is processed at the N and C terminal ends to HBeAg, a secretory protein (upper panel). In the mutant virus, a G-A mutation at nucleotide 1896 in the precore region results in a premature stop codon at codon 28 preventing the production of HBeAg (lower panel). The pregenomic RNA is translated to the core protein (HBcAg); it is also translated to the polymerase protein and reverse transcribed into HBV DNA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8238=[""].join("\n");
var outline_f8_2_8238=null;
var title_f8_2_8239="Taxonomy cereal grains";
var content_f8_2_8239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Taxonomic relationships of major cereal grains",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 530px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Kasarda DD. Nucleic acid (cDNA) and amino acid sequences of alpha-type gliadins from wheat (Triticum aestivum). Proc Natl Acad Sci U S A 1984; 81:4712.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_2_8239=[""].join("\n");
var outline_f8_2_8239=null;
